Clinical Pharmacokinetics in Infants and Children: A Reappraisal

Clinical Pharmacokinetics

Volumn 17, Issue 1, 1989, Pages 29-67

  Kearns, Gregory L ^a   Reed, Michael D ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; PLASMA PROTEIN;

AGE; BACTERIAL MENINGITIS; BODY WATER; CHILD; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG DISPOSITION; DRUG METABOLISM; HUMAN; INFANT; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD;

ADOLESCENT; AGING; CHILD; CHILD, PRESCHOOL; HUMAN; INFANT; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 0024835315     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-198900171-00005     Document Type: Article

References (329)

1. Cardiac transplantation in children and adolescents
2. Percutaneous absorption of Chlorhexidine in neonatal cord care
3. Correlative study of hydrochloric acid, pepsin and intrinsic factor secretion in newborns and infants
4. Drug metabolism in normal children, lead-poisoned children and normal adults
5. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate
6. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations
7. Maturational changes in theophylline and caffeine metabolism and disposition: clinical implications
8. Clinical aspects of developmental pharmacology and toxicology
9. Developmental patterns of renal functional maturation compared in human neonates
10. Pharmacokinetics and drug distribution during postnatal development
11. Pharmacokinetics following epidural morphine in children
12. Cyclosporine in insulin-dependent diabetes mellitus
13. Pharmacokinetics of cefotaxime in neonates
14. Immaturity of the entero-hepatic circulation in early life: factors predisposing to ‘physiologic’ maldigestion and cholestases
15. Iron poisoning
16. Pharmacokinetics of chloramphenicol in cystic fibrosis patients
17. Serum bile acids in newborns and children
18. Duodenal-motility patterns in infants and children
19. Intravenous cefotaxime in children with bacterial meningitis
20. Gentamicin disposition in children with chronic renal failure
21. Principles of drug biodisposition in the neonate: a critical evaluation of the pharmacokinetic-pharmacodynamic interface (part I)
22. Principles of drug biodisposition in the neonate; a critical evaluation of the pharmacokinetic-pharmacodynamic interface (part II)
23. Cyclosporin A: pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogeneic bone-marrow grafts
24. Chloramphenicol and cardiotoxicity
25. Estimation of kinetic parameters from a two-point determination of the drug cumulation factor
26. Clinical pharmacology of intrathecal methotrexate, II: an improved dosage regimen derived from age-related pharmacokinetics
27. Measurement of cyclosporine levels in samples obtained from peripheral sites and indwelling lines
28. Pharmacokinetics and cerebrospinal fluid penetration of ceftazidime in children with meningitis
29. Cephalosporin therapeutics in cystic fibrosis
30. Serum alkaline phosphatase in cystic fibrosis
31. Pharmacokinetics of theophylline in young children with asthma: comparison of rectal enema and suppositories
32. Pharmacokinetics in children
33. Cyclosporine: experience with therapeutic drug monitoring
34. Cimetidine use in children with cystic fibrosis: inhibition of hepatic drug metabolism
35. Cystic fibrosis: a casualty of detoxification?
36. The chest roentgenogram in cystic fibrosis: a new scoring system
37. Comparison of high-pressure liquid chromatography and microbiological assay for the determination of biliary elimination of ciprofloxacin in humans
38. Chloramphenicol dosage and pharmacokinetics in infants and children
39. Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis
40. A urinary metabolite ratio that reflects systemic caffeine clearance
41. Instrumentation and techniques for therapeutic drag monitoring
42. Gastric emptying in preterm infants
43. Michaelis-Menten pharmacokinetics of diphenylhydantoin and application in the pediatric age patient
44. Hexachlorophene storage in a burn patient associated with encephalopathy
45. Pancreatic enzyme preparation with special reference to enterically coated microspheres of pancrelipase
46. Giving drugs per rectum for systemic effect
47. Cyclosporine: a new immunosuppressive agent for organ transplantation
48. Use of cyclosporine in pediatric renal transplant recipients
49. Malabsorption of oral antibiotics in humans and rats with giardiases
50. Systemic absorption of aminoglycosides instilled through the endotracheal tubes of ten hospitalised patients
51. Nonlinear metabolic disposition of theophylline
52. The renaissance of chloramphenicol
53. Pharmacokinetics of ciprofloxacin in cystic fibrosis
54. Rectal drug administration: clinical pharmacokinetic considerations
55. Antibiotic pharmacokinetics in cystic fibrosis: differences and clinical significance
56. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia
57. Rectal absorption of diazepam in epileptic children
58. The effect of exocrine pancreatic function on chloramphenicol pharmacokinetics in patients with cystic fibrosis
59. Blood levels of diazepam after single rectal administration in infants and children
60. Bronchial secretion levels of amikacin
61. Gastric acidity on the first day of life
62. Gentamicin dosing in the newborn: use of a one-compartment open pharmacokinetic model to individualize dosing
63. The bioavailability of chloramphenicol from different routes of administration in children
64. Indications for pediatric liver transplantation
65. Acidosis as a presenting feature of chloramphenicol toxicity
66. A model for dosing gentamicin in children and adolescents that adjusts for tissue accumulation with continuous dosing
67. Methotrexate
68. Treatment and prevention of infections of cerebrospinal fluid shunts
69. Effect of potent topical steroids on plasma Cortisol levels of infants and children with eczema
70. The growth and maturation of human glomeruli and proximal convolutions from term to childhood
71. Effects of cyclosporine in severe systemic lupus erythmatosus
72. Proposed regulations for the study of new drugs in children
73. Aminoglycoside clearance in patients with cystic fibrosis
74. Methemoglobinemia in a hospital nursery
75. Phenobarbital maintenance dose requirements in treating neonatal seizures
76. Cyclosporine: a new and promising immunosuppressive agent
77. Intestinal bile acid malabsorption in cystic fibrosis: a primary mucosal cell defect
78. Pre- and postoperative rectal metronidazole for the prevention of wound infection in childhood appendicitis
79. The effect of fever on antipyrine metabolism in children
80. Body composition during growth: in vivo measurements and biochemical data correlated to differential anatomical growth
81. Water distribution in the foetus and newborn infant
82. Cardiac function and acute chloramphenicol toxicity
83. Effect of asphyxia on theophylline clearance in newborns
84. The influence of asphyxia on phenobarbital dosing requirements in neonates
85. Cyclosporin A in children with persistent renal transplant rejection and progressively deteriorating graft function
86. Cyclosporine controversies
87. Individualizing phenobarbitone dosing in neonates
88. Evaluation of trimethobenzamide hydrochloride (Tigan) suppositories for treatment of nausea and vomiting in children
89. Cyclosporine for juvenile dermatomyositis
90. The importance of pharmacokinetics for paediatrics
91. Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis
92. Development of the human gastrointestinal tract: a review
93. Neonatal population pharmacokinetics of phenobarbital derived from routine clinical data
94. Clinical pharmacokinetics: pediatric considerations
95. Determinants of drug disposition and effect in the fetus
96. Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysis
97. Bioavailability of oral antibiotics in cystic fibrosis
98. Gastric retention in neonates
99. Fecal sterols in infants: bile acids and steroids
100. Quantitative assessment of exocrine pancreatic function in infants and children
101. First-dose and steady-state pharmacokinetics of valproic acid in children with seizures
102. Theophylline absorption in young asthmatic children receiving sustained-release formulations
103. Effect of reduced barometric pressure on drug action and metabolism in mice
104. Enteral absorption and bioavailability in relation to age
105. Theophylline: a ‘state of the art’ review
106. Theophylline
107. Individualizing gentamicin dosage in patients with cystic fibrosis: limitations to pharmacokinetic approach
108. The gastric secretion of infants at birth
109. Bile salt metabolism in the first year of life
110. Antimicrobial chemotherapy in cystic fibrosis patients
111. Perinatal renal pharmacology
112. Age differences in trimethoprim pharmacokinetics: need for revised dosing in children
113. Comparison of patterns of fecal bile acid and neutral sterol between children and adults
114. Morphological findings in the liver of children with cystic fibrosis: a light and electron microscopical study
115. Cyclosporine treatment of autoimmune chronic active hepatitis
116. Quantitative deposition of aerosolized gentamicin in cystic fibrosis
117. International Workshop on Perinatal and Pediatric Aspects of Clinical Pharmacology. Medical, ethical and legal aspects of clinical trials in pediatrics. European Journal of Clinical Pharmacology 18: 121–127, 1980
118. Circadian variation in theophylline disposition in asthmatic children
119. Theophylline disposition in cystic fibrosis
120. Nephrotoxicity of cyclosporine in liver transplantation
121. Pharmacokinetic modeling of bidirectional transfer during peritoneal dialysis
122. Parent-to-child transplantation with cyclosporine immunosuppression
123. Pharmacologic studies in neonates given large dosages of ampicillin
124. Pharmacokinetic profile of trimethoprim-sulfamethoxazole in man
125. The effect of age on alkaline phosphatase and other serologic liver function tests in normal subjects and patients with cystic fibrosis
126. Effective and efficient use of drug level measurements to guide medication dosing
127. Bone marrow transplantation
128. Introduction to pharmacokinetics: aminoglycosides in cystic fibrosis as a prototype
129. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis
130. Absence of a pharmacokinetic interaction between chloramphenicol and acetaminophen in children
131. Gentamicin pharmacokinetics in cystic fibrosis
132. Use of ‘model substrates’ to evaluate hepatic drug clearance in cystic fibrosis
133. The absorption of topical corticosteroids with particular reference to percutaneous absorption in infancy and childhood
134. Antibiotic use in cystic fibrosis
135. Pharmacokinetics of tobramycin in cystic fibrosis
136. Nephrotoxicity of cyclosporine A
137. Effect of cyclosporine on the kidney
138. Relationship of motility to flow of contents in the human small intestine
139. Endotracheally administered antibiotics for gram-negative bronchopneumonia
140. Report of the task force on diagnosis and management of meningitis
141. Plasma diazepam in infants after rectal administration in solution and by suppository
142. The use of theophylline clearance in pediatric status asthmaticus, I: interpatient and intrapatient theophylline clearance variability
143. A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn
144. Hypothesis for the individualization of drug dosage
145. Pharmacologic interactions among chloramphenicol, Phenytoin and phenobarbital
146. Intravenous aminophylline in patients with cystic fibrosis
147. Cephalosporins
148. Glomerular filtration rate during the period of adaptation to extrauterine life
149. Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients
150. Impact of development of the gastrointestinal tract on infant feeding
151. Problems in drug therapy for pediatric patients
152. Diversity of bile acids in the fetus and newborn infant
153. Antibiotic activity in sputum
154. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study
155. Metabolism and pharmacokinetics of acetaminophen in a severely poisoned young child
156. Digoxin inactivation by the gut flora in infancy and childhood
157. Rectal premedication in children: use of diazepam, morphine and hyoscine
158. Plasma levels of thiopentone after premedication with rectal suppositories in young children
159. Comparison of in vitro drug metabolism by lung, liver and kidney of several common laboratory species
160. Ethics of drug studies in infants: how many samples are required for accurate estimation of pharmacokinetic parameters in neonates?
161. Treatment of acute pneumonia in infants and children
162. Development of anaerobic fecal flora in healthy newborn infants
163. Treatment of acute organophosphate poisoning: evidence of a direct effect on central nervous system by 2-PAM (pyridine-2-aldoxime methylchloride)
164. Pharmacokinetic observations of Phenytoin disposition in the newborn and young infant
165. Individualization of Phenytoin dosage regimens
166. Intravenous administration of kanamycin and gentamicin in newborn infants
167. Consensus report: antimicrobial therapy for bacterial meningitis in infants and children
168. Renal clearance of gentamicin in cystic fibrosis
169. Clinical pharmacokinetics: a pediatric overview
170. Application of pharmacokinetics in the diagnosis of chemical abuse in Munchausen syndrome by proxy
171. Skin diseases
172. Medical progress: the pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis
173. Pharmacokinetics of ceftriaxone in neonates and infants with meningitis
174. Bioavailability of phenobarbital by rectal administration
175. Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers
176. Dose dependency for absorption and elimination rates of theophylline: implications for studies of bioavailability
177. Small intestinal motility patterns in the perinatal period
178. Acetaminophen elimination kinetics in neonates, children and adults
179. Special pharmacokinetic considerations in children
180. Toxicity of cyclosporine during treatment with androgens
181. Ontogenic development of gastrointestinal motility, IV: duodenal contractions in preterm infants
182. Clinical pharmacokinetics in neonates
183. Development of physiological variables important for drug kinetics
184. Clinical pharmacokinetics in newborns and infants: age related differences and therapeutic implications
185. The cardiovascular system in cystic fibrosis
186. Cyclosporine-associated chronic nephropathy
187. Bioavailability and clearance of chloramphenicol after intravenous chloramphenicol succinate
188. Developmental aspects of the hepatic cytochrome P450 mono-oxygenase system
189. Comparison of intravenous and rectal aminophylline in the acute ill asthmatic child
190. Absorption of ampicillin and nalidixic acid by infants and children with acute shigellosis
191. Studies on the quality of pancreatic preparations: enzyme content, prospective bioavailability, bile acid pattern and contamination with purines
192. Basic principles in pharmacokinetics
193. Rectal absorption from aspirin suppositories in children and adults
194. Effects of development, aging and renal and hepatic insufficiency as well as hemodialysis on the plasma concentrations of albumin and alpha 1 acid glycoprotein: implications for binding of drugs
195. Blood-brain barrier: interface between internal medicine and the brain
196. Gastrointestinal manifestations of cystic fibrosis: a review
197. Drug absorption in gastrointestinal disease with particular reference to malabsorption syndromes
198. Tobramycin disposition in patients on continuous ambulatory peritoneal dialysis
199. Intraventricular vancomycin: observations of tolerance and pharmacokinetics in two infants with ventricular shunt infections
200. Risk factors affecting infiltration of periphral venous lines in infants
201. Effect of age and serum creatinine on endogenous digoxin-like substances in infants and children
202. Development of alcohol dehydrogenase activity in the human liver
203. Phenobarbital pharmacokinetics in neonates
204. Individualization of drug dosage regimens
205. Clinical pharmacokinetics of changes in drug elimination in children
206. Drug disposition in cystic fibrosis: progress in under-standing pathophysiology and pharmacokinetics
207. Effect of rifampin on chloramphenicol levels
208. Management of acute iron poisoning
209. Cyclosporine kinetics in renal transplantation
210. Absorption of iodine in the neonate following topical use of povidone iodine
211. Mechanisms of drug absorption and their development
212. Drugs and protein binding
213. Transport through membranes and development of membrane transport
214. Endotracheal drug therapy in cardiopulmonary resuscitation
215. Basic principles of drug disposition and action in infants and children
216. Changes in drug metabolism during child growth
217. Clinical pharmacokinetics in infants and children
218. Kinetics of carbamazepine in epileptic children
219. Current concepts in clinical therapeutics: bacterial meningitis in children
220. Use of intravenous iron dextran injection in children receiving total parenteral nutrition
221. Single-dose plasma and cerebrospinal fluid pharmacokinetics of ceftriaxone in infants and children
222. Dosing implications of rapid elimination of trimethoprim-sulfamethoxazole in patients with cystic fibrosis
223. Lack of correlation between clinical response and sputum quantitative cultures in patients with cystic fibrosis
224. Lack of unique ciprofloxacin pharmacokinetic characteristics in patients with cystic fibrosis
225. Hepatic drug clearance in children with leukemia: changes in clearance of model substrates during remission-induction therapy
226. An update on sodium valproate
227. Chloramphenicol: clinical pharmacology in pediatrics
228. The one-point method in predicting dosage regimen in case of hepatic and/or renal failure in presence or absence of change in volume of distribution
229. Intravenous administration of medication in pediatric patients: problems and solutions
230. Pharmacokinetics: basic principles and clinical application
231. Special considerations in drug therapy in infants
232. Concentration guidelines for parenteral antibiotics in fluid-restricted patients
233. Acute iron poisoning: a review
234. Pentachlorophenol poisoning in a nursery for newborn infants, I: clinical features and treatment
235. Blood volume changes in patients with cystic fibrosis
236. Elimination of indocyanine green by the liver of infants with hypertrophic pyloric stenosis and the icteropyloric syndrome
237. Cyclosporin induced remission in autoimmune enteropathy
238. Role of blood flow in hypoxia-induced alterations in hexobarbital metabolism in rats
239. Acetaminophen overdose in children and adolescents
240. The pharmacokinetics of rectal midazolam for premedication in children
241. The effect of antimicrobial agents on fecal flora in children
242. Renal transplantation without steroids
243. Report of a workshop: pathophysiology of bacterial meningitis — implications for new management strategies
244. Dose-dependent kinetics for theophylline: observations among ambulatory asthmatic children
245. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients
246. Kinetic model for gentamicin dosing with the use of individual patient parameters
247. Theoretical and practical considerations of antibiotic therapy for bacterial meningitis
248. Practical pharmacokinetic techniques for drug consultation and evaluation, I: use of dosage regimen calculations
249. Trimethoprim metabolites in rat, dog and man: qualitative and quantitative studies
250. Serum immunoglobulin levels in cystic fibrosis
251. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection
252. Review of rectal suppositories, 1: formulation and manufacture
253. Absorption of chloramphenicol sodium succinate after intramuscular administration in children
254. Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections
255. Pediatric renal transplantation
256. Editorial comment: therapeutic orphans
257. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation
258. Long-term study of one hundred five patients with cystic fibrosis
259. Cyclosporin A induced remission in autoimmune enteropathy
260. Pharmacokinetic properties of netilmicin in newborn infants
261. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic anti-bacterial regimens
262. Pharmacology of chloramphenicol
263. Bronchial tree penetration of antibiotics
264. Low-dose cyclosporine therapy combined with standard immunosuppression in pediatric renal transplantation
265. Unidirectional absorption of gentamicin from the peritoneum during continuous ambulatory peritoneal dialysis
266. Altered drug disposition in cystic fibrosis: are several mechanisms responsible?
267. Cloxacillin absorption and disposition in cystic fibrosis
268. Ceftriaxone therapy of meningitis and serious infections
269. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis
270. Effect of maturation on drug disposition in pediatric patients
271. Effects of cyclosporine in recent-onset juvenile type I diabetes: impact of age and duration of disease
272. Endotracheal tobramycin in gram-negative pneumonitis
273. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics
274. Deposition and clearance of inhaled particles
275. Nonlinear theophylline metabolism
276. A new prognostic score and clinical evaluation system for cystic fibrosis
277. Cyclosporine experience in renal transplantation in children
278. Cyclosporine-induced remission of relapsing nephrotic syndrome in children
279. Methotrexate bioavailability after oral and intramuscular administration in children
280. Cystic fibrosis: a review of pulmonary infections and interventions
281. Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis
282. The influence of age on drug metabolism
283. Clinical pharmacology of hexachlorophene in newborn infants
284. Pharmacokinetics of theophylline and bioavailability of a sustained release theophylline preparation in patients with cystic fibrosis
285. The inter-digestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine
286. Diumal variation in cyclosporine kinetics
287. Rapid prediction of steady-state serum theophylline concentration in patients treated with intravenous aminophylline
288. Blood levels of drug at the equilibrium state after multiple dosing
289. Localization of cystic fibrosis locus to human chromosome 7 cen-q22
290. Crossover pharmacokinetic analysis comparing intravenous and intraperitoneal administration of tobramycin
291. Bile salt metabolism in the newborn: measurement of pool size and synthesis by stable isotope technique
292. Chloramphenicol in the newborn infant: a physiologic explanation of its toxicity when given in excessive dose
293. Influence of food and diet on gastrointestinal drug absorption: a review
294. Interactions affecting drug absorption
295. Cefotaxime therapy of bacterial meningitis in children
296. Rapid estimation of serum theophylline clearance in children with acute asthma
297. Cystic fibrosis
298. Glomerular filtration rate, effective renal blood flow and maximal tubular-excretory capacity in infancy
299. Clinical pharmacokinetics of digoxin in infants
300. Cardiovascular drugs, II: digoxin
301. Gama benzene hexachloride poisoning in children
302. Clinical pharmacokinetics in pediatrics
303. Pediatric pharmacology: who will test the drugs?
304. Pragmatic assessment of medicines available for young children and pregnant or breast-feeding women
305. Efficacy, disposition and pharmacodynamics of aspirin, acetaminophen and choline salicylate in young febrile children
306. Renal toxicity of cisplatin in children
307. Penetration of antimicrobial agents into bronchial secretions
308. Cyclosporine: pharmacokinetics, metabolism and drug interactions
309. Cystic fibrosis: diagnosis, treatment, and prognosis
310. What is a ‘pulmonary exacerbation’ in cystic fibrosis?
311. State of the art: cystic fibrosis
312. Central nervous system infections
313. Carbamazepine intoxication following the use of erythromycin in children
314. Guidelines for ethics in research. Revised Declaration of Helsinki
315. Cyclosporine
316. Pharmacokinetics of intravenous cyclosporine in bone marrow transplant patients: comparison of two assay methods
317. Age-dependent cyclosporine pharmacokinetics in marrow transplant recipients
318. Development and differences of intestinal flora in the neonatal period in breast-fed and bottle-fed infants
319. Aminoglycosides
320. Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay
321. The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patients: age related differences as compared to adults
322. Exocrine pancreas function in premature and fullterm neonates